Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

KarX-EC

Small molecule · Agonist of M1 muscarinic acetylcholine receptor (CHRM1) · developed by Bristol-Myers Squibb

Phase 3 Most advanced trial

BMY Developer

1 Registered trials

What is KarX-EC?

KarX-EC (xanomeline enteric capsules, BMS-986519) is a small-molecule M1 muscarinic acetylcholine receptor agonist being studied in Alzheimer disease with agitation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Targets: M1 muscarinic acetylcholine receptor (CHRM1)
Mechanism: Agonist of M1 muscarinic acetylcholine receptor (CHRM1)
Therapy area: Neurology
Developer: Bristol-Myers Squibb (BMY)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06937229	Phase 3	Alzheimer Disease	Recruiting	BMY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AgitationAlzheimer Disease

Other drugs acting on CHRM1

Xanomeline FDA approved Xanomeline And Trospium FDA approved

More from Bristol-Myers Squibb

Apixaban FDA approved Belatacept FDA approved Deucravacitinib FDA approved Ipilimumab FDA approved Lisocabtagene Maraleucel FDA approved Luspatercept FDA approved Mavacamten FDA approved Nab-paclitaxel FDA approved Nivolumab FDA approved Ozanimod FDA approved Relatlimab FDA approved Repotrectinib FDA approved

Sources

ClinicalTrials.gov NCT06937229

Updated Oct 3, 2026. Something wrong or missing? Report it on the BMY page.

Follow BMY, the company behind KarX-EC

See BMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMY catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z